Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Virpax Pharmaceuticals, Inc. (VRPX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 3.4 | 1.8 | 2.2 | 7.8 | 6.1 | 5.3 | 13.5 | 3.4 |
| Revenue growth | -44.2% | -65.6% | -83.7% | 132.2% | 134.3% | 94.4% | | 60.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 3.4 | 1.8 | 2.2 | 7.8 | 6.1 | 5.3 | 13.5 | 3.4 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 2.1 | 0.5 | 2.3 | 5.0 | 2.9 | 2.0 | 3.3 | 1.7 |
| General and administrative | 2.1 | 0.5 | 2.3 | 5.0 | 2.9 | 2.0 | 3.3 | 1.7 |
| Research and development | 1.3 | 1.2 | 0.3 | 2.8 | 3.3 | 3.3 | 1.7 | 1.7 |
| Other operating expenses | 3.2 | 1.7 | 3.1 | 7.7 | 5.9 | 5.1 | 12.0 | 3.2 |
| EBIT [+] | -3.2 | -1.6 | -3.6 | -7.7 | -5.9 | -5.1 | -3.6 | -3.2 |
| EBIT growth | -45.1% | -69.2% | -1.5% | 137.4% | 156.1% | 118.2% | | 95.5% |
| EBIT margin | -95.0% | -86.8% | -162.5% | -98.5% | -96.6% | -96.9% | -26.9% | -96.4% |
| Non-recurring items | | 0.1 | -0.5 | | | | 0.5 | |
| Interest expense | | | | | | | 0.0 | 0.0 |
| Interest expense | | | | | | | 0.0 | 0.0 |
| Other income (expense), net | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 |
| Pre-tax income | -3.1 | -1.5 | -3.0 | -7.6 | -5.9 | -5.1 | -4.1 | -3.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -3.1 | -1.5 | -3.0 | -7.6 | -5.9 | -5.1 | -4.1 | -3.2 |
| Net margin | -91.3% | -83.6% | -136.4% | -97.6% | -96.3% | -97.2% | -30.6% | -95.4% |
| |
| Basic EPS [+] | ($0.27) | ($0.13) | ($0.26) | ($0.65) | ($0.50) | ($0.44) | ($0.62) | ($0.53) |
| Growth | -47.1% | -70.4% | -58.6% | 22.0% | 6.3% | -27.3% | | -1.6% |
| Diluted EPS [+] | ($0.27) | ($0.13) | ($0.26) | ($0.65) | ($0.50) | ($0.44) | ($0.62) | ($0.53) |
| Growth | -47.1% | -70.4% | -58.6% | 22.0% | 6.3% | -27.3% | | -1.6% |
| |
| Shares outstanding (basic) [+] | 11.7 | 11.7 | 11.7 | 11.7 | 11.7 | 11.7 | 6.7 | 6.0 |
| Growth | 0.0% | 0.0% | 75.4% | 94.8% | 136.2% | 196.8% | | 91.3% |
| Shares outstanding (diluted) [+] | 11.7 | 11.7 | 11.7 | 11.7 | 11.7 | 11.7 | 6.7 | 6.0 |
| Growth | 0.0% | 0.0% | 75.4% | 94.8% | 136.2% | 196.8% | | 91.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|